Burjeel Holdings, a GCC‑based super‑specialty healthcare group listed on the Abu Dhabi Securities Exchange, priced a $500 million Regulation S 5‑year senior unsecured sukuk due 2031 on 31 May 2024. The issuance, the first MENA healthcare sukuk since 2018, was oversubscribed 3.2 times, signalling strong investor appetite for the company’s credit profile and the UAE capital market.
Pricing and Investor Demand
The sukuk was priced at a 7.000 % profit rate with a yield of 7.125 %, the lowest 5‑year yield recorded by a GCC‑based private non‑investment‑grade corporate issuer since 2020. Initial pricing guidance had been in the mid‑7 % range, but the orderbook—peaking at $1.6 billion—allowed Burjeel to tighten terms. International investors received 61 % of the final allocation, led by the United Kingdom (34 %) and US offshore investors (24 %). GCC investors accounted for the remaining 39 %, reflecting broad regional participation.
Transaction Structure and Ratings
The sukuk is part of Burjeel’s newly created $1.5 billion Senior Unsecured Sukuk Programme and will be admitted to trading on the London Stock Exchange’s International Securities Market, subject to customary closing conditions. The offering was coordinated globally by Citi, Emirates NBD Capital and FAB, with Emirates NBD Capital and FAB also serving as sukuk structuring agents. Joint lead managers and bookrunners included ADCB, ADIB, Dubai Islamic Bank, RAKBANK and Sharjah Islamic Bank. S&P Global Ratings assigned a BB+ rating and Moody’s rated the sukuk Ba2, confirming its non‑investment‑grade status.
Use of Proceeds and Strategic Context
Net proceeds will be applied in accordance with the offering documents, primarily to refinance existing debt and to support Burjeel’s strategic priorities. The company highlighted the need for greater financial flexibility to fund advanced clinical care, research, medical education and AI‑enabled healthcare innovation. Dr Shamsheer Vayalil, Chairman and CEO, said the strong demand “reflects investor recognition of Burjeel’s strategy, credit fundamentals, and ability to deliver sustainable growth,” and noted that the transaction broadens the group’s access to global capital markets.
Key Takeaways
- Burjeel Holdings priced a $500 million 5‑year senior unsecured sukuk at a 7.000 % profit rate, yielding 7.125 %, the lowest 5‑year yield for a GCC private non‑investment‑grade issuer since 2020.
- The offering was 3.2 times oversubscribed, with an orderbook of $1.6 billion and final allocation split 61 % to international investors (UK 34 %, US offshore 24 %) and 39 % to GCC investors.
- Proceeds will be used to refinance debt and fund strategic initiatives, including advanced clinical care, research, medical education and AI‑enabled healthcare innovation.
TechInsyte's Take
The pricing and oversubscription suggest that high‑quality investors remain comfortable with non‑investment‑grade healthcare issuers in the GCC, especially when backed by strong credit ratings. While the sukuk expands Burjeel’s financing toolkit, the ultimate impact will depend on how effectively the proceeds are deployed across its clinical and AI initiatives. Executives should monitor the group’s debt profile and any subsequent capital‑raising activity for signals on market depth and pricing trends in the region’s healthcare sector.
Source: Businesswire
